Related Experiment Video
Updated: Jan 11, 2026

In Vivo Modeling of the Morbid Human Genome using Danio rerio
Published on: August 24, 2013
From Radiocopper to Cold Copper: Mechanistic Modeling and Simulation to Define Clinical Response Criteria and
Andreas Lindauer1, Bernard Benichou2, Gloria González Aseguinolaza3
1Calvagone SAS, Chazay d'Azergues, France.
None:
We developed a comprehensive, mechanistic model of human copper metabolism to support biomarker qualification for VTX-801, an adeno-associated vector-based gene therapy which is being developed to restore the mutated ATP7B copper transporter gene in Wilson disease (WD). The model integrates physiological copper kinetics with pathophysiological features of WD by distinguishing between ceruloplasmin-bound and non-ceruloplasmin-bound copper (NCC), and by explicitly incorporating ATP7B-dependent processes: biliary excretion and ceruloplasmin loading of copper. Literature-derived time-activity data from healthy subjects, heterozygous carriers, and WD patients, as well as clinical radiocopper data in plasma and feces from a pilot study in non-WD subjects, were used for model development and validation. VTX-801's dose-response was quantified in WD mouse models using ceruloplasmin oxidase activity measurement and 64Cu fecal excretion. This enabled derivation of activity factors (AFs) corresponding to restored ATP7B function, with 15% and 40% selected as minimal and optimal efficacy targets. Simulations linked AFs to clinical biomarkers, demonstrating that the 48/2-h plasma radioactivity ratio can effectively differentiate VTX-801 responders from non-responders, providing a decision criterion to safely withdraw standard treatment in participants of a phase 1/2 trial. To broaden applicability beyond radiotracer studies, we simulated "cold" copper kinetics under steady-state conditions, deriving expected values for plasma copper, NCC, urinary copper excretion, and relative exchangeable copper (REC). These simulations suggest that REC may also serve as a suitable and simpler to implement, non-radioactive biomarker for ATP7B gene therapy. This model provides a robust quantitative framework to assess copper-related biomarkers in WD and their response to treatment in silico. Trial Registration: EudraCT number: 2019-001157-13.
More Related Videos
07:41Modeling Fast-scan Cyclic Voltammetry Data from Electrically Stimulated Dopamine Neurotransmission Data Using QNsim1.0
Published on: June 5, 2017
08:15Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
Related Concept Videos
In Vitro Drug Dissolution: Compendial Testing Models I
In Vitro Drug Dissolution: Compendial Testing Models II